Interferon (IFN)-related GO terms were significantly enriched in the negative immune response group (Figure 3B), consistent with constitutive type I IFNs (IFN-α and IFN-β) facilitating glioma-related immune escape (Silginer et al., 2017), unfavorable prognosis, chemotherapy resistance, and more aggressive immune response (Zhu et al., 2019). The gene discussed is IFNA1; the disease is central nervous system cancer.